• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "December, 2023"
 Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
0
By Nascent Biotech
In Uncategorized
Posted December 19, 2023

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Marble Arch Research: What is Pritumumab and How it Works
0
By Nascent Biotech
In Corporate News, News
Posted December 6, 2023

Marble Arch Research: What is Pritumumab and How it Works

CLICK HERE TO DOWNLOAD COMPLETE PDF

READ MORE
 2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer
0
By Nascent Biotech
In News, Science News
Posted December 6, 2023

2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer

CLICK TO DOWNLOAD PDF

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.